TY - JOUR
T1 - Pharmacological and clinical profile of recently approved second-generation antipsychotics
T2 - Implications for treatment of schizophrenia in older patients
AU - Rado, Jeffrey
AU - Janicak, Philip G.
PY - 2012/10
Y1 - 2012/10
N2 - Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high comorbidity rates (both psychiatric and medical) in the elderly; age-related changes in pharmacokinetics that lead to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia. We then focus on the potential role of the most recently approved second-generation antipsychotics, paliperidone (both the extended-release oral formulation and the long-acting injectable formulation), iloperidone, asenapine and lurasidone, given the limited clinical experience with these agents in the elderly. While there is limited data to support their safety, tolerability and efficacy in older patients with schizophrenia, each has unique characteristics that should be considered when used in this population.
AB - Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high comorbidity rates (both psychiatric and medical) in the elderly; age-related changes in pharmacokinetics that lead to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia. We then focus on the potential role of the most recently approved second-generation antipsychotics, paliperidone (both the extended-release oral formulation and the long-acting injectable formulation), iloperidone, asenapine and lurasidone, given the limited clinical experience with these agents in the elderly. While there is limited data to support their safety, tolerability and efficacy in older patients with schizophrenia, each has unique characteristics that should be considered when used in this population.
UR - http://www.scopus.com/inward/record.url?scp=84874582243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874582243&partnerID=8YFLogxK
U2 - 10.1007/s40266-012-0009-0
DO - 10.1007/s40266-012-0009-0
M3 - Review article
C2 - 23018584
AN - SCOPUS:84874582243
SN - 1170-229X
VL - 29
SP - 783
EP - 791
JO - Drugs and Aging
JF - Drugs and Aging
IS - 10
ER -